← Eichor
Study identifier: NCT06314230 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Australian Genomics Of Chronic Allograft Dysfunction Study

Condition: Kidney Transplant Rejection · Kidney Transplant; Complications  ·  Sponsor: Western Sydney Local Health District

PhaseN/A
Planned participants500
Who can joinAll sexes, 18 Years to 75 Years
Healthy volunteersNo

About this study

The goal of the Australian Genomics of Chronic Allograft Dysfunction (AUSCAD) study is a single centre (Westmead Hospital), prospective, observational study, which enrols patients at time of kidney (or kidney-transplant) transplant and tracks the post transplant course. The AUSCAD study aims to generate new knowledge and improve outcomes following kidney transplantation. The primary aim is to determine whether important outcomes (including chronic rejection and graft loss) are correlated with patterns of allograft reactivity, gene expression and susceptibility profiles.

This description comes directly from the study's public registry record.

Talk to the study team

Jennifer SY Li, MBBS, FRACP  ·  jennifer.li@health.nsw.gov.au

Philip J O'Connell, MBBS, FRACP  ·  philip.oconnell@sydney.edu.au

Always discuss trial participation with your own doctor first.

Locations (2)

Westmead HospitalWestmead, New South Wales, AustraliaRecruiting
Westmead Institute for Medical ResearchWestmead, New South Wales, AustraliaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06314230